Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Shares Decline 7.4 Percent on Discounted Share Offering

NEW YORK, March 8 (GenomeWeb News) - Shares of Cepheid were down 7.4 percent, or $.68, at $8.47 in afternoon trading today after the company said it was pricing a secondary stock offering below Wednesday's closing price.


As GenomeWeb News reported this morning, Cepheid said it had priced 10 million shares to total $80.5 million, or an individual share price of $8.60, versus Tuesday's closing price of $9.15. This represented an 11.4-percent discount over Tuesday's closing price.


The underwriters of the offering have an option to purchase up to an additional 1.5 million shares to cover over-allotments.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.